InMed to Participate in Upcoming Investor Conferences in April and May 2022
April 19 2022 - 7:30AM
InMed Pharmaceuticals Inc.
(“
InMed” or the “Company”) (Nasdaq:
INM), a leader in the research, development,
manufacturing and commercialization of rare cannabinoids, announces
that the Company's executive team will be participating in several
investor events throughout April and May 2022.
Benzinga Spring Cannabis Capital
ConferenceDate: April 20 - 21,
2022Location: Fontainebleau Miami Beach,
FloridaRegistration: Those interested in
attending the event can register here.
Management will be available for virtual
one-on-one meetings with institutions and industry representatives.
To request 1-on-1 meetings with the Company please contact investor
relations at ir@inmedpharma.com.
Canaccord Genuity’s 6th
Annual Global Cannabis
ConferenceDate: May 11,
2022Location:
VirtualPresentation: The webcast recording
will be available on InMed’s investor relations
website here.
Management will be available for virtual one-on-one meetings
with institutional and corporate clients of the firm. To request
1-on-1 meetings with the Company, please contact your Canaccord
institutional representative. More information on the Canaccord
Cannabis Conference can be found here.
H.C. Wainwright Global Investment
ConferenceDate: May 23 - 26,
2022Location: VirtualPresentation:
The webcast recording will also be accessible on InMed’s investor
relations website and can be found here.
Management will be available for virtual one-on-one meetings
with institutional and corporate clients of the firm. To request
1-on-1 meetings with the Company, please contact your H.C
Wainwright institutional representative.
About InMed: InMed
Pharmaceuticals is a global leader in the research, development,
manufacturing and commercialization of rare cannabinoids. Together
with its subsidiary BayMedica LLC, the Company has unparalleled
cannabinoid manufacturing capabilities to serve a spectrum of
consumer markets, including pharmaceutical and health and wellness.
InMed is also a clinical-stage company developing a pipeline of
rare cannabinoid therapeutics and dedicated to delivering new
treatment alternatives to patients that may benefit from
cannabinoid-based pharmaceutical drugs. For more information,
visit www.inmedpharma.com and www.baymedica.com.
Investor Contact: Colin ClancySenior Director,
Investor RelationsT: +1.604.416.0999E: cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: being a global leader in the research,
development, manufacturing and development of rare cannabinoids;
having unparalleled cannabinoid manufacturing capabilities to serve
a spectrum of consumer markets, including pharmaceutical and health
and wellness; presenting at the Benzinga Spring Cannabis Capital
Conference, April 20 - 21, 2022, the Canaccord 6th Annual Cannabis
Capital Conference on May 11, 2022 and the H.C. Wainwright Global
Investment Conference on May 23 - 26, 2022; and developing a
pipeline of rare cannabinoid therapeutics and dedicated to
delivering new treatment alternatives to patients that may benefit
from cannabinoid-based pharmaceutical drugs.
With respect to the forward-looking information
contained in this news release, InMed has made numerous
assumptions. While InMed considers these assumptions to be
reasonable, these assumptions are inherently subject to significant
business, economic, competitive, market and social uncertainties
and contingencies.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein. A complete discussion
of the risks and uncertainties facing InMed’s stand-alone business
is disclosed in InMed’s Annual Report on Form 10-K and other
filings with the Security and Exchange
Commission on www.sec.gov.
All forward-looking information herein is
qualified in its entirety by this cautionary statement, and InMed
disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Mar 2024 to Apr 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Apr 2023 to Apr 2024